These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3342467)

  • 1. Chemotherapy for relapsed and resistant acute nonlymphoblastic leukemia. Effect of ATA, an amsacrine-containing regime.
    Liang R; Chan TK; Todd D
    Cancer Chemother Pharmacol; 1988; 21(1):68-70. PubMed ID: 3342467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
    Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
    Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined chemotherapy with m-amsacrine in high-risk patients with acute non-lymphocytic leukemia.
    Maschmeyer G; Hiddemann W; Kreutzmann H; Wendt F
    Onkologie; 1987 Feb; 10(1):18-21. PubMed ID: 3295621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.
    Linkesch W; Michlmayr G; Gerhartz H; Illinger H; König H; Düllmann J; Keilhauer R; Moldrzyk D
    Onkologie; 1989 Feb; 12(1):8-10. PubMed ID: 2654791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential pilot studies of intensive postremission chemotherapy for acute nonlymphocytic leukemia.
    Petti MC; Avvisati G; Tafuri A; Meloni G; Amadori S; Mandelli F
    Ann N Y Acad Sci; 1987; 511():436-41. PubMed ID: 3326472
    [No Abstract]   [Full Text] [Related]  

  • 6. The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study.
    Larson RA; Day RS; Azarnia N; Bennett JM; Browman G; Goldberg J; Gottlieb A; Grunwald H; Miller K; Raza A
    Br J Haematol; 1992 Oct; 82(2):337-46. PubMed ID: 1419816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
    Jehn U; Heinemann V; Wilmanns W
    Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
    Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED
    J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine.
    Jehn U; Heinemann V
    Ann Hematol; 1993 Mar; 66(3):131-4. PubMed ID: 8471658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
    Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
    Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
    Wiernik PH; Cassileth PA; Leong T; Hoagland HC; Bennett JM; Paietta E; Oken MM;
    Leuk Lymphoma; 2003 Sep; 44(9):1515-21. PubMed ID: 14565653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose cytosine arabinoside, daunomycin and 6-thioguanine in relapsed or refractory acute nonlymphocytic leukemia.
    Garewal H; Durie BG; Greenberg B
    Oncology; 1987; 44(6):333-5. PubMed ID: 3684173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etoposide in combination with cytarabine, doxorubicin, and 6-thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age.
    Bern MM; Wallach SR; Arkin CF; Lokich JJ; Huberman MS; Anderson NR; Corkery JC; Paul SD; Phillips DF; Sonneborn HA
    Cancer Treat Rep; 1987 Feb; 71(2):201-3. PubMed ID: 3802115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomized study.
    Martiat P; Ghilain JM; Ferrant A; Doyen C; Delannoy A; Chatelain C; Bosly A; Michaux JL; Sokal G
    Eur J Haematol; 1990 Sep; 45(3):164-7. PubMed ID: 2226729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia.
    Fenaux P; Tertian G; Castaigne S; Tilly H; Leverger G; Guy H; Bordessoule D; Leblay R; Le Gall E; Colombat P
    J Clin Oncol; 1991 Sep; 9(9):1556-61. PubMed ID: 1805818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
    Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
    Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial.
    Stein RS; Vogler WR; Winton EF; Cohen HJ; Raney MR; Bartolucci A
    Leuk Res; 1990; 14(10):895-903. PubMed ID: 2259226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.
    Stevens RF; Hann IM; Wheatley K; Gray RG
    Br J Haematol; 1998 Apr; 101(1):130-40. PubMed ID: 9576193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.